Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes

Vaccine. 2002 Mar 15;20(13-14):1741-53. doi: 10.1016/s0264-410x(02)00031-2.


The undesirable side effects and variable efficacy of some oral live rotavirus vaccines in infants have necessitated alternative vaccine approaches. We evaluated a recombinant RFVP2/WaVP6 rotavirus-like-particle (2/6VLP) oral vaccine, using an immunostimulating complex (ISCOM) matrix as adjuvant, in a gnotobiotic (Gn) pig model of human rotavirus (HRV) disease. The 2/6VLPs adhered to the ISCOM-matrix (2/6VLP-ISCOM ) and were antigenic, but they failed to induce protection. However, when combined with attenuated (Att) HRV for oral priming, the 2/6VLP-ISCOM vaccine was effective as a booster and induced partial protection against virulent Wa HRV. The 250 microg 2/6VLP dose was more effective than 100 microg. The highest mean numbers of IgA antibody secreting cells evaluated by ELISPOT in intestinal lymphoid tissues were in pigs receiving AttHRV+2/6VLP-ISCOM or three doses of AttHRV and were associated with the highest protection rates.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Animals
  • Antibodies, Viral / biosynthesis
  • Antibody-Producing Cells / immunology
  • Germ-Free Life
  • Humans
  • ISCOMs / administration & dosage*
  • Immunoglobulin A / biosynthesis
  • Immunoglobulin G / biosynthesis
  • Intestines / immunology
  • Lymphoid Tissue / immunology
  • Rotavirus / immunology*
  • Rotavirus / pathogenicity
  • Swine
  • Vaccines, Synthetic / administration & dosage
  • Viral Vaccines / administration & dosage*


  • Antibodies, Viral
  • ISCOMs
  • Immunoglobulin A
  • Immunoglobulin G
  • Vaccines, Synthetic
  • Viral Vaccines